Allarity Therapeutics, Inc.
ALLR
$1.07
-$0.06-5.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.47M | 1.59M | 2.31M | 2.07M | 2.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -798.00K | -- | -5.00K | -- | -800.00K |
| Total Operating Expenses | 7.32M | 2.61M | 3.37M | 4.24M | 4.88M |
| Operating Income | -7.32M | -2.61M | -3.37M | -4.24M | -4.88M |
| Income Before Tax | -7.45M | -11.97M | -1.63M | -3.85M | -1.64M |
| Income Tax Expenses | 0.00 | -377.00K | -- | -4.00K | 83.00K |
| Earnings from Continuing Operations | -7.45M | -11.59M | -1.63M | -3.84M | -1.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.45M | -11.59M | -1.63M | -3.84M | -1.72M |
| EBIT | -7.32M | -2.61M | -3.37M | -4.24M | -4.88M |
| EBITDA | -7.32M | -2.61M | -3.37M | -4.24M | -4.87M |
| EPS Basic | -1.72 | -7.71 | -3.34 | -- | -- |
| Normalized Basic EPS | -1.08 | -0.90 | -2.04 | -- | -- |
| EPS Diluted | -1.72 | -7.71 | -3.34 | -- | -- |
| Normalized Diluted EPS | -1.08 | -0.90 | -2.04 | -- | -- |
| Average Basic Shares Outstanding | 4.33M | 1.58M | 499.30K | -- | -- |
| Average Diluted Shares Outstanding | 4.33M | 1.58M | 499.30K | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |